Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2021-01-25 Regulatory Filings
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-01-25 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) related to the registration of shares of common stock for resale by selling stockholders. It details the terms of the offering, the securities involved, risk factors, use of proceeds, and other related information typical of a prospectus used in securities offerings. It is not a financial report, earnings release, management discussion, or any other type of corporate filing related to financial results or governance. Instead, it is a capital markets document related to financing and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus, not a brief announcement or regulatory filing.
2021-01-22 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from KemPharm, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a formal communication related to a securities registration process, specifically a request for the SEC to declare the registration statement effective by a certain date and time. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory filing related to securities registration and acceleration request, not a financial report or earnings release. The document length is short (1785 characters), and it is a formal correspondence with the SEC. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2021-01-20 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, form names, fiscal period dates, or document titles that would allow identification of a specific filing type. The text does not include any indication of being a report, announcement, certification, or any other recognizable financial or corporate filing document. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as a catch-all category for filings that do not fit other specific categories.
2021-01-19 English
KEMPHARM, INC.
Major Shareholding Notification
2021-01-14 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by KemPharm, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for sale to the public. The text includes details about the securities being registered, the selling stockholders, and the terms of the offering. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report. Hence, the classification is CAP with high confidence.
2021-01-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.